PDF(Pubmed)
Abstract：
Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging globally as a significant problem. The mainstay of treatment is lifestyle intervention (LSI). We hypothesized that providing information regarding LSI and MASLD through a social media application generally used in the respective society would improve clinical outcomes in MASLD more than standard of care (SOC). This is a randomized controlled study in noncirrhotic MASLD patients aged 18-65 years in Thailand. Eligible patients were randomly assigned to either the control (SOC) or intervention arm. Patients in both groups received standard LSI advice. Infographics about MASLD and LSI information were sent to the intervention group every 3-7 days via the LINE official account. The outcomes are changes in liver steatosis and liver stiffness by FIBROSCAN at 24 weeks, as well as weight loss, body composition, and serum alanine aminotransferase (ALT) level between the two groups. A total of 122 patients were enrolled. The median age of eligible participants was 53 years, 64.7% were female, and median body mass index was 27.3 kg/m2. After a complete 24-week study period, both groups had an improvement in weight, ALT level, liver steatosis, and fat mass, but the differences in those changes between groups were not statistically significant. Interestingly, a significant improvement in liver stiffness was observed in the intervention group than in the control group (- 0.7 ± 1.8 kPa vs. 0.1 ± 2.4 kPa, P = 0.035). Encouraging LSI and delivering MASLD information via a social media application (LINE official account) to patients with MASLD demonstrated a better outcome of liver stiffness measurement than SOC.Clinical trial number: TCTR20210304002 (04/03/2021) ( http://www.thaiclinicaltrials.org/show/TCTR20210304002 ).
摘要：
代谢功能障碍相关的脂肪变性肝病（MASLD）正在全球范围内成为一个重要问题。治疗的主要方法是生活方式干预（LSI）。我们假设，通过各自社会中普遍使用的社交媒体应用程序提供有关LSI和MASLD的信息将比标准护理（SOC）改善MASLD的临床结果。这是一项针对泰国18-65岁非肝硬化MASLD患者的随机对照研究。符合条件的患者被随机分配到对照（SOC）或干预组。两组患者均接受标准LSI建议。每3-7天通过LINE官方帐户将有关MASLD和LSI信息的信息图发送到干预组。结果是FIBROSCAN在24周时肝脏脂肪变性和肝脏硬度的变化，以及减肥，身体成分,两组患者血清谷丙转氨酶(ALT)水平比较。共纳入122例患者。符合条件的参与者的平均年龄为53岁，64.7%为女性，中位体重指数为27.3kg/m2。经过一个完整的24周的研究期，两组的体重都有改善，ALT水平,肝脏脂肪变性,和脂肪，但组间这些变化的差异无统计学意义.有趣的是,与对照组相比，干预组肝硬度显着改善（-0.7±1.8kPavs.0.1±2.4kPa,P=0.035)。鼓励LSI并通过社交媒体应用程序（LINE官方帐户）向MASLD患者提供MASLD信息，证明肝脏硬度测量结果比SOC更好。临床试验编号：TCTR20210304002(04/03/2021)(http://www.thaiclinicaltrials.org/show/TCTR20210304002)。
